Mon, Oct 20, 2014, 11:03 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Immune Pharmaceuticals, Inc. Message Board

  • simabuzz simabuzz Aug 16, 2009 11:27 AM Flag

    ** Accounting firm raised going concern issue**

    Our recurring losses from operations and our stockholders’ deficit raise substantial doubt about our ability to continue as a going concern and, as a result, our independent registered public accounting firm included an explanatory paragraph in its report on our consolidated financial statements
    http://www.secinfo.com/dsvr4.suf6.htm
    As a result, the Company has an accumulated deficit of $225.8 million as of June 30, 2009. The Company’s recurring losses from operations and the accumulated deficit raise substantial doubt about its ability to continue as a going concern.

    I wonder why EPCT management did not mention this during CC? This is not good news.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • << the treatment is distributed by IDIS>>

      There's indeed an attempt to do so...Refresh my memeory! What were the numbers management wrote down in their 10Q or mentioned during the CC?

    • "My opinion is less effective then managements'or accounting firm opinion...I prefer to stick to those two. They have THE specific internal EPCT knowledge. My opinion would be one, filled with hope; prefer to stick to management wording."


      Is there a demand from patients before and after the reimbursment agreements, or not?

      If you yourself got the diagnosis, would you wait 3-4 month for an agreement or would you tell your doctor to order a cycle of Ceplene and pay the first 1/3 part of the treatment yourself?

      It is you who have made an interpretation of the word "meningful" income. You insinuated that there is no demand from patients around the world, that they do not know the treatment and that IDIS have administrative problems distrubuting orders from doctors around the world.

      If patients recieves Ceplene or not have n o t h i n g to do with the question of how Epicept is runned, the treatment is distributed by IDIS. End of story.

    • My opinion is less effective then managements'or accounting firm opinion...I prefer to stick to those two. They have THE specific internal EPCT knowledge. My opinion would be one, filled with hope; prefer to stick to management wording.

      I'm convinced that IDIS can deliver an order! Not convinced they can deliver thousands of them...Also not convinced that IDIS is focussing on increasing share. They're nothing more then a delivery firm!
      IDIS connects...Nothing more
      http://www.idispharma.com/

      QED

    • What news will trigger a pps increase of at least 50%? No significant milestones ahead!

    • Could you explain the american tax legislation to me?

      Do you find a positive impact here?:
      "As a result, the Company has an accumulated deficit of $225.8 million as of June 30, 2009."

      Do you find any impact on the daily work in the CO and the financial situation upto Q2 2010, when sales of Ceplene is predicted as "meningful"?

      • 1 Reply to larshansson18
      • Do you find any impact on the daily work in the CO and the financial situation upto Q2 2010, when sales of Ceplene is predicted as "meningful"?

        Your intention of your 1st 2 questions is to create a huray-for-deficit-atmosphere which sounds ridiculous to me and probably all other investors who are seriously interested in a profit generating company and not only in a revenue-for-deficit generating company.

        Your 3rd question reflects perfectly what I did mention in my earlier message,...

        a) a prediction = a message of hope
        b) meaningfull = not defined, no reference
        c) Q2 2010 = too late to prevent EPCT from another emmsion
        d) Delisting in September or in January 2010, will have serious financial consequences (as mentioned in my earlier message)
        e) If delisted a serious partner will be hard to find
        f) No serious milestones until late 2010 (milestones which will impact pps before September or otherwise January 2010)

    • You are new at this, aren't you? That paragraph is standard for 90% of the small biotecks. It was there last time too, and the time before that...

      • 1 Reply to dknospam
      • Yes, that's why I did my DD! On this MB, I only see positive messages or messages of hope. None is realistic! Give you another example...

        On August 3, 2009, the Company received a letter from the Nasdaq Listing Qualifications Department stating that the Company had not regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2) by July 28, 2009 and, as a result, its common stock would be subject to delisting from The Nasdaq Capital Market unless the Company requests an appeal before the Nasdaq Hearings Panel (the “Panel”). The Company intends to request a hearing before the Panel, which will stay the delisting of its common stock pending the issuance of a decision by the Panel following the hearing. The Company expects that the hearing will be scheduled for September 2009. At the hearing, the Company will request continued listing on The Nasdaq Capital Market based upon its plan for demonstrating compliance with the applicable listing requirements. Pursuant to the Nasdaq Marketplace Rules, the Panel has the authority to grant the Company up to an additional 180 days from August 3, 2009 (i.e. January 30, 2010) to implement its plan of compliance. There can be no assurance that the Panel will grant the Company’s request for continued listing on The Nasdaq Stock Market.
        http://www.secinfo.com/dsvr4.suf6.htm

        It means that Delisting is imminent, within 1 month! I've not seen 1 message about this...NONE. Don't try to twist this one as well. Unless, you've facts which show otherwise.

 
IMNP
3.02-0.13(-4.13%)Oct 20 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Apple Inc.
NasdaqGSMon, Oct 20, 2014 4:00 PM EDT